Objective: Although the relationship between apolipoprotein E (ApoE) gene polymorphisms and the risk of Parkinson disease (PD) has been established, the results were inconsistent and inconclusive.
Introduction
Apolipoprotein E (Apo-E), plays a key role in lipid metabolism, is considered as one of the most powerful genetic risk factors for Alzheimer disease (AD). [1] [2] [3] Three common polymorphisms (e2, e3, and e4) and 6 genotypes (e2/e2, e3/e3, e4/e4, e3/e2, e4/e2, e4/ e3) were included in the ApoE gene. The e3 allele is predominant in all populations, followed by e4 and e2 alleles. While, the frequencies of e2, e3, and e4 varied among populations. [4] [5] The APOE gene, especially for the e4 allele, was identified to be a susceptible factor for AD and lower age at disease onset. [6] [7] In addition, Parkinson disease (PD) was revealed to share some clinical, neurochemical, and pathologic features with AD. [8] For example, patients with PD frequently develop dementia, and patients with AD often develop parkinsonism. [9] Both the 2 diseases are characterized by neuronal death and protein deposition (eg, amyloid or a-synuclein). [10] For these reasons, the APOE gene has been hypothesized to be an important susceptible factor for PD.
Previous studies have evaluated the role of APOE in dementia associated with PD. [11] [12] In contrast to AD, the results on the genetic association between APOE polymorphisms and PD were controversial. The APOE e4 allele was a major susceptible factor for sporadic PD in Spain, [13] Mexican, [14] and Indian [15] populations. However, most of other publications have reported no significant association between the APOE e4 allele and PD risk. [16] [17] [18] In contrast, the APOE e2 allele seems to occur with lower frequency in PD, which indicated a protective factor for APOE e2 allele in PD. Pulkes et al [19] and Li et al [20] have shown that the frequency of APOE e2 allele in PD were significantly higher than that in the control group in Thailand and Chinese populations. While, most of other researches suggested no association between APOE e2 and PD risk. [21] [22] Furthermore, the APOE genotype e2/e4 was reported to be associated with an increased risk of PD in Japanese population. [21] The APOE genotype e3/e4 was reported to be associated with an increased risk of PD in Mexican [23] and Indian [15] populations. While, this positive results cannot be replicated in other studies. [24] [25] Considered the relatively small sample size and contradictory conclusions in individual study, we attempt to performed a metaanalysis of existing studies to clarify whether APOE alleles (e2, e3, and e4) and genotype contributes significantly to the risk of PD.
Materials and methods

Patient and public involvement
There was no patient and public involvement in present metaanalysis. An ethical approval is not necessary for a meta-analysis.
Literature search strategy
This meta-analysis followed the Cochrane collaboration definition and PRISMA 2009 guidelines for meta-analysis and systematic review. [26] A exhaustive search was performed through Embase, Cochrane Library, PubMed, and Chinese National Knowledge Infrastructure (CNKI) data bases for relevant studies using the following terms: "apolipoprotein E," "APOE," "polymorphism," "single nuclear polymorphism (SNP)," "Parkinson disease," "PD." No language and published year were limited. Other relevant references of identified studies were retrieved by cross-references.
Inclusion/exclusion criteria
The following criteria were used for the literature inclusion: articles should concern APOE polymorphism and PD risk; casecontrol and/or cohort designed studies; contained SNP genotype data both in case and control groups; adequate data for the calculation of odds ratios (ORs) and 95% confidence intervals (CIs); and the genotype distribution in control groups was in Hardy-Weinberg equilibrium (HWE). In addition, studies were excluded when they were: studies that contained overlapping data with other literature; data came from case-reports, reviews or abstracts; not case-control and/or cohort designed studies; genotype frequencies were unavailable; and control group did not confirm to HWE.
Data extraction
Two independent authors (JL and LL) simultaneously selected the relevant articles according to the inclusion and exclusion criteria and performed the data extraction process. The following terms were extracted: the first author, published year, ethnicity, age, gender, genotyping methods, diagnostic criteria, number of cases and controls, and number of genotype. All discrepancies were resolved by a consensus achieved by a third author (JML).
Quality assessment
The Newcastle-Ottawa Scale (NOS) was used to evaluate the study quality. [27] Adequacy of case definition, representativeness of the cases, selection of controls, definition of controls, comparability cases/controls, comparability cases/controls, same method of ascertainment, and non-response rate were taken into account and given a corresponding score. Total score ranged from 0 (lowest quality) to 8 (highest quality). A study with a score of 6 or higher was classified as high quality.
Statistical analyses
All statistical analyses were performed using the STATA 12.0 (StataCorp, College Station, TX) and Revman 5 (Cochrane Collaboration, London, United Kingdom). The strength of relationship between APOE e2, e3, e4 alleles, e2e2, e2e3, e2e4, e3e3, e3e4, and e4e4 genotypes and PD susceptibility was evaluated using crude ORs with 95% CI. Subsequently, stratified analyses by ethnicity were also performed out. A x 2 -based Cochran Q test and Higgins I 2 statistic was used to evaluate the between-study heterogeneity of the studies. A P value of less than .05 was considered significant. I 2 values of >50% indicate heterogeneity among studies. A fixed effect model (the MantelHaenszel method) was adopted if there was no significant heterogeneity (I 2 < 50%). Otherwise, the random effect model (the DerSimonian and Laird method) was used. The stability of the results was assessed using sensitivity analysis, which omitting single study each time to evaluate the influence of each study on the pooled OR. Funnel plots were used to assess publication bias by the methods of Begg test and Egger test. A t test was performed to determine the significance of the asymmetry. An asymmetric plot suggested possible publication bias (P ≥ .05 suggests no bias).
Results
Characteristics of the published studies
As shown in Figure 1 , a total of 2584 studies were retrieved initially. 957 studies were excluded for duplicated data. After reviewing the titles, abstracts, and full texts, 1475 were excluded for not related to the genetic association between APOE gene polymorphism and PD risk. And 105 were excluded for being review, short communication, letter, and conference abstract. Finally, 47 individual studies were enrolled in present metaanalysis. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Among these studies, 16 were conducted in Chinese population, 27 were in Caucasian population, and 4 were in Latin American population. The quality assessments and NOS scores for each study were list in Table 1 [ [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] and Table s1 , http://links.lww.com/MD/C565.
Meta-analysis: APOE alleles and PD
The results of the association between APOE alleles and PD risk were listed in Table 2 . A total of 47 studies reported the relation of APOE e2, e3, and e4 and PD. and significant association between APOE e2 and PD were observed (P = .04, OR [95% CI] = 1.23 [1.01, 1.50]), suggesting this allele might be a risk factor for PD. Both the distributions of APOE e3 and e4 were not statistically different in PD population and healthy population (P > .05) ( (Table 3) .
Test of heterogeneity
Significant heterogeneity was detected in allele models of APOE e2, e3, and e4 (Table 2) . Therefore, subgroup analysis stratified Table 1 Characteristics of included studies. [20] 1998 Chinese 58.8 ± 12.6/NA 40.3/NA PCR-RFLP DSM-IV 52 438 Qin et al [56] 1998 Chinese 66. [59] 2004 Chinese 67.4 ± 10.2/69.4 ± 11.4 27.5/36.5 PCR-RFLP DSM-IV 36 52 Whitehead et al [69] 1996 Iran 56.9 ± 6.6/58.0 ± 7.1 34.9/37.7 NA NA 189 162 Kiyohara et al [21] 2011 Japanese 68.5 ± 8.68/69.7 ± 5.63 61.8/61/5 TaqMan DSM-IV 238 296 Pulkes et al [19] 2011 Thailand NA 43.5/NA PCR-RFLP DSM-IV 155 158 Singh et al [15] [53] 1997 Japanese NA 60.8/NA PCR-RFLP NA 163 576 Buchanan et al [22] [31] 1999
Netherland NA NA PCR-RFLP MMSE 199 96 Eerola et al [33] [49] 2002
American NA NA NA NA 166 94 Harrington et al [41] 1994 UK 77.7 ± 7.1/78.1 ± 7.7 49.0/51.7 TaqMan NA 51 58 Arai et al [29] 1994
American NA NA NA DSM-III-R 98 48 Gao et al [36] [44] 1995 American 67.4 ± 7.9/69.9 ± 6.5 37.7/52.6 PCR-dot-blot NA 61 78 Rubinsztein et al [50] 1994 UK NA NA PCR-RFLP NA 33 34 Williams-Gray et al [11] 2009 UK 62.5 ± 12.8/NA 40/52 Taqman DSM-IV 505 478 Ghebremedhin et al [37] 2006 UK 75.1 ± 6.9/73.4 ± 7.4 42.6/42.6 PCR-RFLP MMSE 108 108 Blázquez et al [13] 2006 Spain 72.0 ± 9.6/70. [47] 1995 USA NA NA PCR-RFLP DSM-III-R 10 243 Helisalmi et al [42] 1996 Finland 71 ± 6/69 ± 8 46.7/53.3 PCR-RFLP NA 100 100 Grasbon-Frodl et al [39] 1999
German NA 70/58.5 PCR-RFLP NA 62 53 Ballering et al [30] 1997
Netherland NA NA NA NA 50 107 Goetz et al [38] [35] 2008 Barcelona 56 ± 8.4/57.4 ± 8.7 NA PCR-RFLP DSM-IV 138 91 Gregório et al [18] 2013 Brazil 69.2 ± 11.1/71.7 ± 8.5 38/52 PCR-RFLP DSM-IV 232 137 Gallegos-Arreola et al [14] 2009 Mexican 63 ± 9/50 ± 14 40/56 PCR-RFLP NA 105 107 López et al [23] 
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by ethnicity was performed. Notable, the significant heterogeneity of allele model of APOE e2, e3, and e4 still exist (Except for APOE e2 in Latin-American population) (P = .27, I 2 % = 24) ( Table 2) . For the genotypes, significant heterogeneity were also detected in e2e4 (P < .0001, I
2 % = 58) and e3e3 (P < .0001, I 2 % = 80). Subgroup analysis stratified by ethnicity shown the significant heterogeneity for e2e4 was only detected in Asian population (P < .0001, I 2 % = 72) but not in Caucasian (P = .47, I 2 % = 0) and Latin-American populations (P = .57, I
2 % = 0). Furthermore, significant heterogeneity for e3e3 were detected in Asian (P = .0004, I 2 % = 64) and Latin-American populations (P < .00001, I 2 % = 98), but not in Caucasian population (P = .31, I 2 % = 11) ( Table 2) .
Sensitivity analysis and publication bias
Sensitivity analysis on the overall risk estimate by excluding one study at a time was confirmed. The ORs were not significantly altered in APOE e2, e3, and e4 allele analysis (Fig. 5) . Begg test and Egger test were used to evaluate publication bias. The P value for Egger linear regression test is shown in Figure 6 . The results revealed that there was no obvious publication bias in overall analysis for e2 (P egger = .367), e3 (P egger = .586) and e4 (P egger = .069) in APOE. 
Discussion
It has suggested that the AD and PD may share several similar pathogenesis. Both the two diseases were characterized by neuronal loss and protein aggregation. [62] And both the clinical features included dementia and extra-pyramidal symptoms. [63] The APOE gene was a major cholesterol carrier that supports lipid transport and injury repair in the brain, which located on chromosome 19q13.2. [64] [65] It was considered to be a plausible candidate gene for influencing the neurodegenerative process in AD, PD and PD dementia (PDD). [66] [67] Among the three alleles (e2, e3, and e4), the APOE e4 was shown to be significantly associated with AD, [67] onset of late onset AD (LOAD), PD, and PDD risk. [23, [67] [68] The APOE e4 is the "risk" variant for several phenotypes compared with other 2 alleles. APOE e3 was considered to be neutral. And APOE e2 generally was considered to be a protective factor in neurodegenerative diseases.
Three studies have reported the association between APOEe2 and/or e4 and PD risk. Whitehead et al [69] has firstly investigated the APOE e4 and PD risk using a case-control study and metaanalysis of 6 studies and shown no significant association between APOE e4 and the risk of PD. Subsequently, Huang et al [70] carried out a meta-analysis with 22 publications and found the APOE e2, but not APOE e4, was positively associated with PD. Five years later, Williams-Gray et al [71] performed a update meta-analysis with 32 articles and detected the APOE e4 was a susceptible factor for PD compared to healthy control. In present meta-analysis, we detected a significant increase of APOE-e2 carriers among PD patients compared to controls. However, no association was observed between APOE-e3 and -e4 and PD risk in overall populations, which was similar with the results reported by Whitehead et al [69] and Huang et al, [70] but different from the results reported by Williams-Gray et al. [71] This inconsistent in the 2 meta-analysis may due to the different number of cases and controls included in the studies. In present study, we included 15 more article than that in Williams-Gray et al, [71] which may increase the power to detect the genetic association between APOE-e4 and PD. However, no subgroup analysis stratified by ethnicity was performed out in previous meta-analysis. For the important role of gene background in PD, subgroup analysis based on ethnicity was carried out. Notable, the genetic association between APOE polymorphisms and PD varied in different populations. The significant association between APOE-e2 and PD risk disappeared in Caucasian, Asian, and Latin-American subgroups. In addition, a statistical genetic association was found between APOE-e4 and PD risk in Asian subgroup, but not in Caucasian and Latin-American subgroups, which might indicate the important role of genetic background in the pathogenesis of PD.
Recent researches have been shown a significant higher totaland LDL-cholesterol levels typically occur with the e4 allele; which, forming monofibrillary peptides, precipitates and forms dense structures (amyloid plaques) that are the main component of neurofibrillary tangles. [72] However, e3 and e2 isoforms have affinity to the Tau protein; which confers protection from hyperphosphorylationon the Tau protein. [73] Our combined analysis suggested the APOE-e4, but not APOE-e2, was the susceptible factor for PD. The inconsistent results in previous meta-analyses may due to the limited number of included studies, as well as the number of subjects. Furthermore, we firstly conducted a subgroup analysis stratified by ethnicity and detected the APOE-e4 was a risk factor for PD only in Asian population, but not in Caucasian and Latin-American populations.
Several limitations were presented in this meta-analysis. First, mixed dementia might exist in included case-control study, which was shown to increase the apparent association of APOE with PD. Second, multiple factors including genetic factors, environmental factors, as well as the interaction of the 2 factors, and other unknown risk factors should be considered in the pathogenesis of PD. Third, the number of studies and subjects was relatively small, especially in Latin-American population. To identify these genetic associations, larger number of case-control designed studies with more subjects is necessary. Table 3 The association between APOE polymorphisms and Parkinson disease. 
Conclusion
Our meta-analysis suggests that APOE e2 is associated with PD in total group and APOE e4 carrier is associated with PD in Asian population. In addition, it provides a support for the risk effect of e2e4 in total group and e3e4 in Latin-American population.
